Cardiovascular Disease Risk Reduction in Type 2 Diabetes

Cardiovascular Disease Risk Reduction in Type 2 Diabetes This infographic provides guidance on reducing cardiovascular disease risk for people with type 2 diabetes.

 

Cardiovascular Disease Risk Reduction in Type 2 Diabetes

PDF preview

This infographic provides guidance on reducing cardiovascular disease risk for people with type 2 diabetes.

Lipid Management in Diabetes

Lipid Management in Diabetes This infographic provides guidance for treating people with type 2 diabetes who are at risk for ASCVD.

 

Lipid Management in Diabetes

PDF preview

This infographic provides guidance for treating people with type 2 diabetes who are at risk for ASCVD.

View the PDF

Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health

PDF Preview

In 2010, the American Heart Association defined a novel construct of cardiovascular health to promote a paradigm shift from a focus solely on disease treatment to one inclusive of positive health promotion and preservation across the life course in populations and individuals. Extensive subsequent evidence has provided insights into strengths and limitations of the original approach to defining and quantifying cardiovascular health. In response, the American Heart Association convened a writing group to recommend enhancements and updates. 

View the PDF

Implementing the ASCVD Risk Calculator Within the PatientVisiting Workflow

Implementing the ASCVD Risk Calculator Within the PatientVisiting Workflow
Implementing the ASCVD Risk Calculator Within the PatientVisiting Workflow

The purpose of the ASCVD Risk Calculator is to estimate a patient’s 10-year ASCVD risk at an initial visit to establish a reference point. The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood- pressure-lowering medication use, diabetes status and smoking status.

View the PDF

Treatment Algorithms and Recommendations for CVD Risk Management, Microvascular Complications and Foot Care and the Pharmacologic Approach to Glycemic Treatment

Treatment Algorithms and Recommendations for CVD Risk Management, Microvascular Complications and Foot Care and the Pharmacologic Approach to Glycemic Treatment
Treatment Algorithms and Recommendations for CVD Risk Management, Microvascular Complications and Foot Care and the Pharmacologic Approach to Glycemic Treatment

There is no greater cause of morbidity and mortality in patients with diabetes than atherosclerotic cardiovascular disease (ASCVD). Diabetes is a risk factor for ASCVD as are medical conditions that are common among individuals with type 2 diabetes (T2D). Multiple studies have demonstrated that significant benefits result from controlling cardiovascular (CV) risk factors in this patient population.

View the PDF

Implementing a Medication Adherence Program Targeting Patients with T2D at Risk for CVD

Implementing a Medication Adherence Program Targeting Patients with T2D at Risk for CVD
Implementing a Medication Adherence Program Targeting Patients with T2D at Risk for CVD

It is difficult to determin the prevalence of medication nonadherence. However, the consequences of individuals not taking their medications as prescribed are clear.

View the PDF

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

Listen to Rodica Busui (Pop-Busui), MD, PhD, Neha J. Pagidipati, MD, MPH, and Jennifer B. Green, MD discuss ASCVD (atherosclerotic cardiovascular disease) progression in patients with type 2 diabetes,strategies to assess its risk, and the COORDINATE study.

Play the podcast in Apple Podcasts.

podcast player graphic

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

2024 Episode 12 – Understanding ASCVD Progression in Patients with Type 2 Diabetes, and Strategies to Assess its Risk

Rodica Busui (Pop-Busui), MD, PhD is the Larry D. Soderquist Professor of Diabetes, Vice Chair Clinical &
Health Outcomes Research Department of Internal Medicine, Director Clinical Research Caswell Diabetes Institute at the University of Michigan, and an international leader in the field of diabetes and diabetes complications. Her research interests involve chronic complications of diabetes, including
diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure, cardiovascular disease, as well as use of novel technologies for diabetes management.

Neha J. Pagidipati, MD, MPH is an Associate Professor of Medicine and cardiometabolic disease prevention specialist at the Duke Clinical Research Institute. She served as the Chief Research Fellow at the DCRI between 2016 and 2017 and has been involved with cardiometabolic disease prevention research since 2011. Currently, she directs the Duke Cardiometabolic Prevention Clinic, and her research focuses on cardiometabolic disease prevention, with particular emphasis on lifestyle modification, weight management, lipid disorders, and diabetes.

Jennifer B. Green, MD is a Professor of Medicine in the Division of Endocrinology at Duke University, a faculty member of the Duke Clinical Research Institute (DCRI) and was Chief of the Endocrinology section at the Durham VA Medical Center from 2003-2017. Dr. Green’s clinical practice and research have focused upon strategies to treat diabetes mellitus and reduce the risk of CV and other disease-related complications. She is presently the Duke University site PI, Publications Committee Co-Chair, and Executive Committee Member for GRADE, a federally-funded, long-term comparative effectiveness study of glucose-lowering medications for type 2 diabetes.

2022 Episode 8 – Life’s Essential 8™

Help patients with diabetes manage their risk for heart disease and stroke. Donald Lloyd-Jones, MD, ScM, FAHA, FACC and Jane EB Reusch, MD, FAHA discuss the recent release of AHA’s Life’s Essential 8 which was expanded from Life’s Simple 7 to include healthy sleep for optimal cardiovascular health as well as other lifestyle factors included in Life’s Essential 8 and how health care professionals can use this checklist to help patients with diabetes manage their risk for heart disease and stroke.

Play the podcast in Apple Podcasts.

podcast player graphic

2022 Episode 8 – Life’s Essential 8™

Life’s Essential 8 Transcript

Donald Lloyd-Jones, MD, ScM, FAHA, FACC is Chair of the Department of Preventive Medicine, the Eileen M. Foell Professor of Heart Research, and Professor of Preventive Medicine, Medicine, and Pediatrics at Northwestern University’s Feinberg School of Medicine. His research interests include the study of the life course and mechanisms of cardiovascular health and healthy aging, and the practice of cardiovascular disease epidemiology, risk estimation, and prevention. He is an author of more than 700
peer-reviewed scientific papers and has been named a “Highly Cited Researcher” (in the top 1% of cited authors in clinical medicine) each year for the past decade. Over the last 15 years, he has been a frequent leader of national clinical practice guidelines and policy statements for AHA, ACC and NHLBI. He has been a national leader for the American Heart Association for two decades and served as AHA
National Board President (2021-22).
Jane EB Reusch, MD, FAHA is Professor of Medicine, Bioengineering, and Integrative Physiology, and Associate Director of the Center for Women’s Health Research, Anschutz Medical Campus at the University of Colorado; Staff Physician and Merit Review Investigator at the Rocky Mountain Regional VAMC. As a physician-scientist, Dr. Reusch has made fundamental contributions to our understanding of cellular metabolism of diabetes and its complications studying people with diabetes and cell and
animal models. She has been elected to the American Society for Clinical Investigation and the American Association of Physicians, and awarded the Women of Valor in Diabetes Award, The Endocrine Society Laureate Award for Mentoring and the Banting Medal for Leadership and Service and Albert Renold Award from the American Diabetes Association. She served as President for Medicine and Science of the American Diabetes Association and on the ADA professional Practice Committee 2019-2021 (writing group for the ADA Standard of Medical Care for Diabetes).
Jane Reusch

Jane E. B. Reusch, MD, FAHA (Center for Women’s Health Research, Anschutz Medical Campus at the University of Colorado; Staff Physician and Merit Review Investigator at the Rocky Mountain Regional VAMC)

2022 Episode 7 – Three Basic Targets

Diabetes is more than a blood sugar problem. Help your patients with type 2 diabetes understand their risk of cardiovascular disease and the importance of blood pressure, lipid, and glucose control in managing risk. Listen to Nathan Wong, PhD, MPH, and Collette Knight, MD, discuss ways for patients to know and understand their numbers in LDL cholesterol, triglycerides, blood pressure, A1C, and more.

Play the podcast in Apple Podcasts.

podcast player graphic

2022 Episode 7 – Three Basic Targets

Download the Episode 7 Transcript

Nathan D. Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC is a cardiovascular epidemiologist and specialist in preventive cardiology. His primary research interests include subclinical atherosclerosis and epidemiology and management of dyslipidemia and diabetes in relation to cardiovascular disease.  Past/current investigator with numerous NIH observational studies on cardiovascular disease and clinical trials of lipid-lowering. Dr. Wong has authored over 400 papers and co-edited seven textbooks and is currently president of the InterAmerican Heart Foundation and past president of the American Society for Preventive Cardiology and Pacific Lipid Association Chapter of the NLA.

Nathan Wong

Nathan Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC (Professor of Medicine and Director, Heart Disease Prevention Program, University of California, Irvine)

Colette M. Knight, MD is the chair of Inserra Family Diabetes Institute, and division director of Endocrinology, Diabetes and Metabolism at Hackensack University Medical Center and associate professor of medicine at Hackensack Meridian School of Medicine.  Dr. Knight is a graduate of Harvard Medical School and completed her internal medicine residency training at New York-Presbyterian/Columbia University Medical Center in New York, followed by a clinical and research fellowship in endocrinology at Albert Einstein College of Medicine & Montefiore Medical Center in the Bronx.  She has had significant experience as a clinician, educator and investigator.  Dr. Knight’s academic interests include diabetes and cardiovascular health and health disparities and diabetes outcomes.  She has been the recipient of awards for teaching, mentoring and excellence in clinical practice.

Colette Knight

Tough Cases: Achieving All “Targets”

Test your knowledge of how to help your patients with type 2 diabetes achieve their blood glucose, blood pressure and lipid targets through coordinated team-based care. Walk through different case-based scenarios with this expert panel and identify opportunities to improve communication, develop treatment plans, and recognize barriers to achieving these targets, using the latest American Diabetes Association and American Heart Association guidelines.

Date: Thursday, September 15, 2022
Time: 4:00 pm – 5:00 pm ET

Learning Objectives:

  • Identify how to use shared decision making to achieve targets related to blood glucose, blood pressure, and lipid management for type 2 diabetes
  • Discuss barriers to achieve targets and solutions to address those barriers.
  • Develop treatment plans based on guideline-directed therapy to help patients achieve targets.

Robert Eckel, MD

Robert Eckel, MD (University of Colorado Hospital)

Om Ganda

Om Ganda, MD (Joslin Diabetes Center)

Sadiya Khan, MD, MSc

Sadiya Khan, MD, MSc (Northwestern Medicine)